Exercise as a mean to control low-grade systemic inflammation.

Mathur N, Pedersen BK. · 2008

Read Exercise as a mean to control low-grade systemic inflammation. by Mathur N, Pedersen BK. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2615833.txt.

Introduction

Mathur and Pedersen argued in 2008 that exercise fights chronic disease partly by calming low-grade inflammation throughout the body. Smouldering inflammation is now seen as a driver of heart disease, type 2 diabetes, and several cancers, which together cause about 60 percent of deaths worldwide. Regular exercise protects against these conditions. The authors propose an anti-inflammatory mechanism centred on muscle.

They highlight IL-6, the first recognised myokine: a signalling molecule produced and released by contracting muscle fibres that acts on other organs. On this view, skeletal muscle is an endocrine organ, an internal gland, whose secretions during activity counter inflammation elsewhere. The authors suggest myokines carry many of exercise's benefits against these diseases. On this view, inactivity itself is a risk factor.

Catalog record

CREATORMathur N, Pedersen BK.
YEAR2008
COLLECTIONPAPERS
FORMATTXT
FILE SIZE34 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2615833

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Exercise as a Mean to Control Low-Grade Systemic Inflammation By Neha Mathur, Bente Klarlund Pedersen Published in: Mediators of Inflammation DOI: 10.1155/2008/109502 ABSTRACT Abstract Chronic noncommunicable diseases (CNCDs), which include cardiovascular disease, some cancers, for example, colon cancer, breast cancer, and type 2 diabetes, are reaching epidemic proportions worldwide. It has now become clear that low-grade chronic inflammation is a key player in the pathogenesis of most CNCDs. Given that regular exercise offers protection against all causes of mortality, primarily by protection against atherosclerosis and insulin resistance, we suggest that exercise may exert some of its beneficial health effects by inducing anti-inflammatory actions. Recently, IL-6 was introduced as the first myokine, defined as a cytokine, which is produced and released by contracting skeletal muscle fibres, exerting its effects in other organs of the body. We suggest that skeletal muscle is an endocrine organ and that myokines may be involved in mediating the beneficial effects against CNCDs associated with low-grade inflammation. 1. INTRODUCTION Chronic noncommunicable diseases (CNCDs) which include cardiovascular conditions (mainly heart diseases and stroke), some cancers, chronic respiratory conditions, and type 2 diabetes, affect people of all nationalities and classes and are reaching epidemic proportions worldwide [1–4]. CNCDs cause the greatest global share of death and disability, accounting for around 60% of all deaths worldwide. Approximately, 80% of chronic-disease deaths occur in low- and middle-income countries and account for 44% of premature deaths worldwide. It is estimated that the number of deaths from these diseases is double the number of deaths that result from a combination of infectious diseases (including HIV/AIDS, tuberculosis, and malaria), maternal and perinatal conditions, and nutritional deficiencies [1]. From a historical perspective, inflammation has been considered as the natural host response to an acute infectious episode, whereas chronic inflammation has been considered a sign of chronic infection. It has now become clear that low-grade chronic inflammation is a key player in the pathogenesis of most NCDCs. There has been an increasing appreciation of the role of inflammation both in the pathogenesis of atherosclerosis [5, 6] and as a key factor in insulin resistance [7]. Low-grade chronic inflammation is characterized by increased systemic levels of some cytokines and C-reactive protein (CRP) and a number of studies have confirmed an association between low-grade systemic inflammation on one hand and atherosclerosis and type 2 diabetes on the other [8]. Physical inactivity has been identified as a stronger predictor of these chronic diseases than risk factors such as hypertension, hyperlipidemia, diabetes, and obesity for all-cause mortality [9]. Moreover, regular physical activity appears to protect against premature death independent of obesity [10, 11]. Regular physical activity offers protection against, and may be useful as a treatment for a wide variety of, chronic diseases associated with low-grade inflammation [12]. The protective effects of regular exercise against diseases such as cardiovascular disease, type 2 diabetes, colon cancer, and breast cancer have been reviewed extensively [13–16]. Recent findings demonstrate that physical activity induces an increase in the systemic levels of a number of cytokines with anti-inflammatory properties [8, 17] and skeletal muscle has recently been identified as an endocrine organ, which produces and releases cytokines (also called myokines) [18, 19]. The discovery of contracting muscle as a cytokine-producing organ opens a new paradigm; skeletal muscle is an endocrine organ that, by contraction, stimulates the production and release of myokines, which may influence metabolism and modify cytokine production in tissue and organs. 2. CHRONIC LOW-GRADE SYSTEMIC INFLAMMATION AND ITS CONSEQUENCES In response to an acute infection or trauma, the cytokines and cytokines inhibitors will increase [20]. The initial cytokines as they appear in the circulation in relation to an acute infection consist of the following: TNF-α, IL-1β, IL-6, IL-1 receptor antagonist (IL-1ra), and soluble TNF-α-receptors (sTNF-R), and IL-10. The systemic response known as the acute-phase response includes the production of a large number of hepatocyte-derived acute phase proteins, such as C-reactive protein (CRP) that is known to be a sensitive marker of systemic inflammation. The response can be mimicked by the injection of the cytokines TNF-α, IL-1β, and IL-6 into laboratory animals or humans [8, 21]. Chronic low-grade systemic inflammation has been characterized by a 2- to 3-fold elevation in the systemic concentrations of proinflammatory and anti-inflammatory cytokines, natural occurring cytokine antagonists, and the acute phase reactant C-reactive protein (CRP) [13, 22]. In the latter case, the stimuli for the cytokine production are not known, but it is assumed that the origin of TNF in chronic low-grade systemic inflammation is mainly the adipose tissue [23–26]. Type 2 diabetes, obesity, and cardiovascular disease are related to a state of low-grade systemic inflammation [7, 27–29]. Despite the fact that the changes in acute-phase reactants are much smaller than those in acute infections, the chronicity of low-grade inflammation is strongly associated with increasing age, lifestyle factors such as smoking and obesity, together with increased risk of cardiovascular disease and type 2 diabetes [22, 25, 30]. Plasma concentrations of IL-6 [31] and TNF-α have been shown to predict the risk of myocardial infarction in several studies [32], and CRP has emerged as a particularly stronger independent risk factor for cardiovascular disease than the low-density lipoprotein cholesterol level [13, 33, 34]. 3. THE DIRECT METABOLIC ROLES OF TNF Growing evidence suggests that TNF-α plays a direct role in metabolic syndrome, via direct effect of TNF-α on insulin signaling [35, 36]. Patients with diabetes demonstrate high expression of TNF-α in skeletal muscle and in plasma, and it is likely that adipose tissue, which produces TNF-α, is the main source of the circulating TNF-α [37–39]. Thus, a number of studies indicate that elevated TNF-α is not secondary to the pathological conditions associated with insulin resistance, but that TNF-α plays a direct pathogenic role in glucose metabolism [29, 40]. After adjustment for multiple confounders, including IL-6, high plasma TNF concentrations are associated with insulin resistance [40]. In cultured cells, TNF-α induces insulin resistance through increased serine phosphorylationof insulin receptor substrate-1 (IRS-1), which subsequently converts IRS-1 to an inhibitor of insulin receptor tyrosinekinase activity [41]. TNF-α has been shown to have a direct (insulin-independent) effecton S6K and ERK-1/2 in cultured cells [42, 43]. In addition, evidence for a direct role of TNF-α in insulin resistance in humans in vivo has been obtained [44]. When TNF-α was infused into healthy humans, we found that TNF-α induces insulin resistance in skeletal muscle, without an effect on endogenous glucose production. TNF-α directly impaired glucose uptake and metabolism by altering insulin signal transduction. TNF-alpha infusion increased phosphorylation of p70 S6 kinase, extracellular signal-regulated kinase-1/2, and c-Jun NH(2)-terminal kinase, concomitant with increased serine and reduced tyrosine phosphorylation of insulin receptor substrate-1. These signalling effects were associated with impaired phosphorylation of Akt substrate 160, the most proximal step identified in the canonical insulin signalling cascade regulating GLUT4 translocation and glucose uptake. Thus, excessive concentrations of TNF-alpha negatively regulate insulin signalling and whole-body glucose uptake in humans. Moreover, it was recently demonstrated that TNF-alpha infusion increases whole-body lipolysis by 40% with a concomitant increase in FFA clearance, but with no changes in skeletal muscle FFA uptake, release, or oxidation [45]. The findings with regard to an effect of TNF on both glucose and fat metabolism provide a direct molecular link

Read the complete text